This process can create a vicious cycle that accelerates the progression of tauopathy.[10] Consequently, targeting Nox, which are responsible for ROS production, presents a highly competitive and promising therapeutic strategy for mitigating the pathological cascade wherein Aβ exacerbates toxic tau, potentially offering new avenues for treating dementia. The gene discussed is MAPT; the disease is dementia.